AbbVie Inc. $ABBV Shares Sold by Broadleaf Partners LLC

Broadleaf Partners LLC cut its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 23.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,763 shares of the company's stock after selling 1,800 shares during the quarter. Broadleaf Partners LLC's holdings in AbbVie were worth $1,207,000 as of its most recent SEC filing.

• AbbVie Stock Eyes Breakout as Pipeline and Profits Grow

Several other large investors have also recently bought and sold shares of ABBV. GAMMA Investing LLC raised its position in AbbVie by 25,841.6% in the first quarter. GAMMA Investing LLC now owns 10,234,737 shares of the company's stock worth $2,144,382,000 after acquiring an additional 10,195,284 shares in the last quarter. Nuveen LLC purchased a new position in AbbVie in the first quarter worth $1,819,154,000. Goldman Sachs Group Inc. raised its position in AbbVie by 31.6% in the first quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company's stock worth $3,068,820,000 after acquiring an additional 3,519,187 shares in the last quarter. Northern Trust Corp raised its position in AbbVie by 11.8% in the fourth quarter. Northern Trust Corp now owns 21,824,626 shares of the company's stock worth $3,878,236,000 after acquiring an additional 2,299,645 shares in the last quarter. Finally, Deutsche Bank AG raised its position in AbbVie by 27.4% in the fourth quarter. Deutsche Bank AG now owns 9,769,102 shares of the company's stock worth $1,735,969,000 after acquiring an additional 2,102,273 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

Insider Transactions at AbbVie

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the transaction, the executive vice president owned 177,292 shares of the company's stock, valued at $35,178,278.64. This represents a 19.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Nicholas Donoghoe sold 13,295 shares of the company's stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the transaction, the executive vice president directly owned 58,247 shares of the company's stock, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.25% of the company's stock.

AbbVie Trading Up 0.4%

• 3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

AbbVie stock opened at $210.2840 on Friday. The stock has a market cap of $371.48 billion, a PE ratio of 100.14, a P/E/G ratio of 1.35 and a beta of 0.50. The stock has a 50-day moving average price of $192.84 and a 200 day moving average price of $192.96. AbbVie Inc. has a 52 week low of $163.81 and a 52 week high of $218.66. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). The company had revenue of $15.42 billion for the quarter, compared to analysts' expectations of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.65 EPS. Equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

• If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were paid a dividend of $1.64 per share. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie's dividend payout ratio is currently 312.38%.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Daiwa America upgraded AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 7th. Daiwa Capital Markets upgraded AbbVie from a "neutral" rating to an "outperform" rating and set a $214.00 price target for the company in a research report on Thursday, August 7th. Piper Sandler assumed coverage on AbbVie in a research report on Tuesday, August 12th. They issued an "overweight" rating and a $231.00 price target for the company. Bank of America raised their price target on AbbVie to $204.00 and gave the company a "hold" rating in a research report on Monday, June 9th. Finally, Citigroup raised their price target on AbbVie to $205.00 and gave the company a "hold" rating in a research report on Wednesday, June 11th. Five equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $214.95.

Read Our Latest Research Report on AbbVie

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Featured Articles

• Five stocks we like better than AbbVie
• The Basics of Support and Resistance
• Equal Weight ETFs: Hidden Upside in Today’s Market
• 5 Top Rated Dividend Stocks to Consider
• Zillow Group Approaching Key Technical Levels: Is It Time to Buy?
• Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
• For True Diversification: 3 Stocks You Can Buy Now

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here